Taaleri Oyj
Taaleri Oyj
11/01/2023 | Press release | Distributed by Public on 11/01/2023 00:17
Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
Taaleri Oyj
11/01/2023 | Press release | Distributed by Public on 11/01/2023 00:17
Please select the service you want to use:
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact